{"id":249894,"date":"2023-05-31T00:00:00","date_gmt":"2023-05-31T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0086-biopharma-osteoporosis-epidemiology-epidemiology\/"},"modified":"2026-04-22T05:16:04","modified_gmt":"2026-04-22T05:16:04","slug":"epidmd0086-biopharma-osteoporosis-epidemiology-epidemiology-dashboard","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0086-biopharma-osteoporosis-epidemiology-epidemiology-dashboard\/","title":{"rendered":"Osteoporosis &#8211; Epidemiology &#8211; Epidemiology Dashboard"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of osteoporosis comprises epidemiological estimates of key patient populations in 45 countries worldwide.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the mature markets and Europe and 10 years for the other countries we cover.<\/p>\n<p>All forecast data are available on Clarivate\u2019s Insights Platform in tabular format, with options to download to osteoporosis Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology\u2019s osteoporosis forecast answers the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of osteoporosis\u00a0over the forecast period?<\/li>\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people at high risk for hip fracture (<abbr title=\"hip fracture\">HF<\/abbr>) or a major osteoporotic fracture (<abbr title=\"major osteoporotic fracture\">MOF<\/abbr>)?<\/li>\n<li>Of all people with osteoporosis, how many in each of the major mature pharmaceutical markets have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with osteoporosis, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<\/ul>\n<p>In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following osteoporosis subpopulations for mature markets:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases<\/li>\n<li>Drug-treated prevalent cases<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-249894","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-osteoporosis","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249894\/revisions"}],"predecessor-version":[{"id":281528,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249894\/revisions\/281528"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}